A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

April 18, 2028

Study Completion Date

April 18, 2029

Conditions
Hodgkin DiseaseLymphoma, T-Cell, PeripheralLymphoma, Large B-Cell, DiffuseLymphoma, Large-Cell, Anaplastic
Interventions
DRUG

PF-08046044/SGN-35C

Given into the vein (IV; intravenously)

Trial Locations (32)

33021

Sylvester Comprehensive Cancer Center - Hollywood, Hollywood

33136

University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center, Miami

University Of Miami Hospitals And Clinics, Miami

33146

Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center, Coral Gables

33176

Sylvester Comprehensive Cancer Center - Kendall, Miami

33442

University of Miami Hospital and Clinics - Deerfield Beach, Deerfield Beach

37134

Centro Ricerche Cliniche di Verona s.r.l., Verona

64064

The University of Kansas Cancer Center - Lee's Summit, Lee's Summit

66160

The University of Kansas Hospital Cambridge Tower A, Kansas City

The University of Kansas Hospital, Kansas City

The University of Kansas Medical Center Medical Office Building, Kansas City

66205

The University of Kansas Cancer Center, Investigational Drug Services, Fairway

University of Kansas Clinical Research Center, Fairway

University of Kansas Cancer Center, Westwood

66210

The University of Kansas Cancer Center - Overland Park, Overland Park

66211

The University of Kansas Cancer Center - Indian Creek Campus, Overland Park

68105

Nebraska Medical Center, Omaha

68118

Nebraska Medicine - Village Pointe, Omaha

68123

Nebraska Medicine - Bellevue Medical Center, Bellevue

68198

University of Nebraska Medical Center, Omaha

91010

City of Hope (City of Hope National Medical Center, City Of Hope Medical Center), Duarte

IP Address: City of Hope Investigational Drug Services(IDS), Duarte

94805

Institut Gustave Roussy, Villejuif

98195

University of Washington, Seattle

California

"University of California San Francisco , HDFCCC - Hematopoietic Malignancies"

08901

Robert Wood Johnson University Hospital, New Brunswick

Rutgers Cancer Institute of New Jersey, New Brunswick

Washington

"Fred Hutchinson Cancer Research Center , Seattle, WA"

DK 2100

Rigshospitalet University Hospital of Copenhagen, Copenhagen Ø

08035

Hospital Universitari Vall d'Hebron, Barcelona

SM2 5PT

The Royal Marsden NHS Foundation Trust (RM), London

M20 4BX

The Christie NHS Foundation Trust, Manchester

All Listed Sponsors
lead

Seagen, a wholly owned subsidiary of Pfizer

INDUSTRY